National Cancer Registration and Analysis Service

Our vision:

To provide near-real time, cost-effective, comprehensive, quality-assured data services covering the entire cancer pathway on all patients in England as a resource for population and public health, patient care, research, quality, safety, clinical team and service performance management, audit, outcome monitoring and commissioning.
The cancer pathway

GENETIC RISK
- Germ-line data

LIFESTYLE
- Risk factors

PRESENTATION
- Screening

DIAGNOSIS
- MDT discussion

TREATMENT
- Surgery

FOLLOW UP
- PROMs

PALLIATIVE CARE
- Palliative care

DEATH
- Death certificates

Socio-demographics
- Co-morbidities

Pathology
- Molecular

Chemotherapy
- Radiotherapy

Relapse/recurrence
- Clinical audit

Quality of Life
- Clinical audit

Primary care
- Imaging

Molecular data
- Surgery

Clinical audit
- Radiotherapy

MDT discussion
- PROMs
The data

2,000 Multidisciplinary team meetings
600 Local secondary care systems
142 Chemotherapy centres
82 Breast screening centres
56 Radiotherapy centres
22 Molecular testing labs
26+ other sources

National data systems and services collect link quality assure and analyse data on every person with cancer in England
Regular NCRAS outputs

Official Statistics
- Cancer incidence
- Cancer mortality
- Cancer survival statistics
- Emergency presentation metrics
- Stage at diagnosis indicators

Annual Updates
- Cancer prevalence
- Routes to diagnosis
- Treatment
- Radiotherapy activity
- Chemotherapy activity
- Recurrence
- Cancer services profiles
- Tobacco profiles
- Alcohol profiles
- Local health cancer indicators
- Childhood cancer statistics
- Practice profiles plus

Tools
- CancerData
- CancerStats
- CAS Explorer
Ovarian Cancer Audit Feasibility Pilot
Disease Profile in England: 2015-2017
Stage data 2017
The proportion of tumours registered with registry stage recorded ranged from 100% to 52.6% amongst the CCGs.

The proportion of tumours diagnosed at early stage (stages 1 and 2) ranged from 62.9% to 21.8%.

Map 30a: Variation in percentage of lung cancer patients diagnosed at an early stage (stage 1 and 2) by CCG

Map 30b: Variation in mortality rate from lung cancer per population by CCG

Map 30c: Variation in percentage of one-year survival estimates for lung cancer patients, all adults aged 15 to 69 years, by year of diagnosis and CCG

Map 30d: Variation in percentage of lung cancer patients diagnosed at an early stage (stage 1 and 2) by CCG

2015-2017
2012-2014
2009-2011


Area name

NHS Trafford CCG
NHS Oxfordshire CCG
NHS Leeds CCG
NHS Stockport CCG
NHS Wigan and Leigh CCG
NHS Manchester CCG
NHS South Tyneside CCG

Significantly higher than England - 99.8% level
Significantly higher than England - 99% level
Not significantly different to England
Significantly lower than England - 99% level
Significantly lower than England - 99.8% level
Suppressed

Clinical Commissioning Group

Percentage (%)
Routes to Diagnosis: Tumours Diagnosed 2006-2016

Proportions of Tumours Diagnosed by Route and Age, Cervix 2016

How to use these graphs

The cancer site of interest can be selected from the drop down menu above, with up to 42 cancer sites and an all cancers (all malignant neoplasms excl. non-melanoma skin cancer) grouping. Only one cancer site will be displayed at a time.

Confidence intervals for the top graph can be turned on or off by clicking the box marked “Display confidence intervals”.

Look at data broken down by
- Age

View trends by
- Age

Year of Interest
- 2016

Site
- Cervix
Routes to Diagnosis: Tumours Diagnosed 2006-2016

Look at data broken down by
- Deprivation

View trends by
- Deprivation

Year of Interest
- 2016

Site
- Colorectal

Display confidence intervals

These graphs show the proportion of incident cancers diagnosed within each group for the chosen attribute, split into each of the eight Routes to Diagnosis.

The top stacked bar graph shows the percentage of cancers diagnosed by route and group for the selected year and cancer site of interest.

The lower graph shows the same information with the same axis, but as a stacked line graph. Here the coloured areas represent the percentage of cancers diagnosed by that route and cancer site for each year.

How to use these graphs

The cancer site of interest can be selected from the drop-down menu above, with up to 42 cancer sites and all cancers (all malignant neoplasms (exc. non-melanoma skin cancer) grouping. Only one cancer site will be displayed at a time.

Confidence intervals for the top graph can be turned on or off by clicking the box marked “Display confidence intervals”.

Proportions of Tumours Diagnosed by Route and Deprivation, Colorectal 2016

Proportions of Tumours Diagnosed by Route and Deprivation, Colorectal 2016
Routes to Diagnosis: Tumours Diagnosed 2006-2016

Proportions of Tumours Diagnosed by Route and Ethnicity, Biliary tract cancer 2006-2016

How to use these graphs
The cancer site of interest can be selected from the drop down menu above, with up to 42 cancer sites and an all cancers (all malignant neoplasms excluding non-melanoma skin cancer) grouping. Only one cancer site will be displayed at a time.

Confidence intervals for the top graph can be turned on or off by clicking the box marked “Display confidence intervals”.

Proportions of Tumours Diagnosed by Route and Ethnicity, Biliary tract cancer 2006-2016

Ethnicity

Proportion of Tumours

11  Strategic Intelligence Forum, Lizz Paley, 27th January 2020
Radiotherapy delivery in England by episodes and attendances

This tool presents the number of radiotherapy episodes and attendances delivered in England.

Click below to download a copy of the data, and for TIFF outputs of the graphs:
Download Aggregated Data

Export Grouped Bar Plot
Export Stacked Bar Plot
Export Grouped Percentage Plot
Export Stacked Percentage Plot

Data for this tool is based on patient-level information collected by the NHS, as part of the care and support of cancer patients. The data is collected, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE).
People in London Living With and Beyond Cancer in 2017 by Cancer Alliance (Diagnosed 1995-2017)

England prevalence 3.5% (3.8% in women, 3.2% in men)

Dashboard generated by the TCST - NCRAS Partnership.
People in England Living With and Beyond Cancer in 2017 by STP, Cancer Alliance and England

Stage of first diagnosis (Diagnosed between 2012-2017)
Deprivation (IMD) Breakdown (Diagnosed between 1998-2017)
Time Since Diagnosis (Diagnosed between 1998-2017)

Dashboard generated by the TCST - NCRAS Partnership.
Resources

Where to find our outputs:
- CancerData
- Legacy website
- Through CADEAS

Feedback:
- Which of these types of analysis are most useful to cancer alliances?
- What would cancer alliances like NCRAS to focus on in future work?
Acknowledgments

Data in these tools and reports is based on patient-level information collected by the NHS, as part of the care and support of cancer patients. The cancer registry data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE).
NCRASenquiries@phe.gov.uk